<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116416">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587625</url>
  </required_header>
  <id_info>
    <org_study_id>Oxytocin high low dose</org_study_id>
    <nct_id>NCT01587625</nct_id>
  </id_info>
  <brief_title>High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour</brief_title>
  <acronym>OxyHighLow</acronym>
  <official_title>High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized control trial conducted in three hospitals in the southwest of Sweden,
      consenting nulliparous women in active phase of labour and with a defined delayed labour
      progress will be randomized to receive a regimen of either high or low dose of oxytocin.
      Primary outcome is caesarean delivery rate. Secondary outcomes are Apgar score &lt; 7 at 5
      minutes, need of neonatal intensive care, hyper-stimulation of contractions, spontaneous
      vaginal birth rate, length of labour, postpartum haemorrhage, sphincter lacerations,
      experienced labour pain, epidural analgesia and the women´s childbirth experience one month
      postpartum (assessed with Childbirth Experience Questionnaire). Study results will
      contribute to establish good evidence-based routines regarding oxytocin treatment of delayed
      labour progress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim is to compare starting dose and increment of amount of oxytocin for augmentation of
      delayed labour to determine whether augmentation by high dose of oxytocin improves labour
      outcomes compared with a low dose of oxytocin, without effecting neonatal outcomes or birth
      experiences negatively.

      Delay in labour, also described as poor progress, due to ineffective uterine contraction is
      a major problem in modern obstetric care and one of the main reasons for the increased rate
      of caesarean deliveries, in particular among nulliparous women. Infusion with synthetic
      oxytocin is a commonly used treatment of hypotonic uterine contractions. Despite the
      widespread use of oxytocin no consensus exists regarding the dosage of oxytocin, both
      starting dose and increment of amount of oxytocin.

      In a randomized control trial conducted in three hospitals in the southwest of Sweden,
      consenting nulliparous women in active phase of labour and with a defined delayed labour
      progress will be randomized to receive a regimen of either high or low dose of oxytocin. The
      expected outcome is a decreased caesarean section rate and increased rate of spontaneous
      vaginal delivery for women with high dose of oxytocin for augmentation, without affecting
      neonatal outcomes or childbirth experiences negatively.

      Primary outcome is caesarean delivery rate. Secondary outcomes are Apgar score &lt; 7 at 5
      minutes, need of neonatal intensive care, hyper-stimulation of contractions, spontaneous
      vaginal birth rate, length of labour, postpartum haemorrhage, sphincter lacerations,
      experienced labour pain, epidural analgesia and the women´s childbirth experience one month
      postpartum (assessed with Childbirth Experience Questionnaire). Based on a sample size
      calculation (α=0.05, β=0.80), 688 women will be needed in each group. Analysis will be
      performed by the intention to treat.

      Study results will contribute to establish good evidence-based routines regarding oxytocin
      treatment of delayed labour progress.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caesarean delivery rate</measure>
    <time_frame>At birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous vaginal birth rate</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of labour</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyper-stimulation of contractions</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum haemorrhage</measure>
    <time_frame>Two hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphincter lacerations</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidural analgesia</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experienced labour pain</measure>
    <time_frame>Two hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Childbirth experience</measure>
    <time_frame>1 month posptartum</time_frame>
    <description>Childbirth Experience Questionnaire (CEQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>Five minutes postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care</measure>
    <time_frame>1 month postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1376</enrollment>
  <condition>Birth; Delayed</condition>
  <arm_group>
    <arm_group_label>High dose of oxytocin infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of oxytocin infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose of oxytocin infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose of oxytocin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon</intervention_name>
    <arm_group_label>High dose of oxytocin infusion</arm_group_label>
    <arm_group_label>Low dose of oxytocin infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy nulliparous women

          -  singleton pregnancy

          -  normal pregnancy

          -  cephalic presentation

          -  spontaneous onset of active labour

          -  at term (37 - 42weeks gestation)

          -  delay or arrest of active labour

        Exclusion Criteria:

          -  Non-Swedish speaking women

          -  previous uterine surgery

          -  intrauterine growth retardation &gt; - 22%

          -  malpresentation at time of inclusion

          -  intrapartal hemorrhage at time of inclusion

          -  nonreassuring fetal-heart pattern at time of inclusion

          -  meconium at time of inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie Berg, PhD, Professor</last_name>
    <phone>+46 31 786 6084</phone>
    <email>marie.berg@gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lotta Selin, Master</last_name>
    <phone>+46 520 911339</phone>
    <email>lotta.selin@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla-Britt Wennerholm, PhD, Ass. professor</last_name>
      <email>ulla-britt.wennerholm@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Marie Berg, PhD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NU Hospital Group</name>
      <address>
        <city>Trollhättan</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lotta Selin, Master</last_name>
      <email>lotta.selin@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Marie Berg, PhD, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>April 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Delayed labour</keyword>
  <keyword>dystocia</keyword>
  <keyword>oxytocin augmentation</keyword>
  <keyword>primiparous women</keyword>
  <keyword>childbirth</keyword>
  <keyword>childbirth experience</keyword>
  <keyword>progress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
